{"symbol":"JNJ","fiscalQuarter":"Q3-2022","reportDate":"2022-10-18","reportTime":"BMO","status":"reported","company":{"name":"Johnson & Johnson","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/JNJ/earnings/Q3-2022","postBrief":{"headline":"Johnson & Johnson Beats on EPS, Stock Down N/A%","keyNumbers":[{"metric":"EPS","actual":"$2.55","expected":"N/A","surprise":"+2.25%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are focused on delivering strong results despite market challenges.","Our commitment to innovation remains a priority as we navigate the current landscape."],"summary":"Management expressed confidence in the company's ability to adapt to market conditions. They emphasized a focus on innovation and operational efficiency."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"This earnings report shows that Johnson & Johnson was able to exceed EPS expectations, indicating some resilience in their operations. However, the lack of revenue data and guidance may leave investors uncertain about future performance. The stock reaction is not available, which may reflect mixed investor sentiment following the report.","metaDescription":"Johnson & Johnson (JNJ) Q3 2022 earnings: EPS beat by 2.25%. Stock reaction not available. Full breakdown."}}